RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Protara Therapeutics Stock

Protara Therapeutics Net Income 2024

Protara Therapeutics Net Income

-64.44 M USD

Ticker

TARA

ISIN

US74365U1079

WKN

A2P4JE

In 2024, Protara Therapeutics's profit amounted to -64.44 M USD, a 59.43% increase from the -40.42 M USD profit recorded in the previous year.

The Protara Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e101.43
2028e39.07
2027e-16.83
2026e-49.94
2025e-67.34
2024e-64.44
2023-40.42
2022-65.95
2021-47.25
2020-33.98
2019-14.99
2018-20.73
2017-36.71
2016-28.53
2015-21.38
2014-9.7
2013-14.03
2012-14.1

Protara Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Protara Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Protara Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Protara Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Protara Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Protara Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Protara Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Protara Therapeutics’s growth potential.

Protara Therapeutics Revenue, EBIT and net profit per share

DateProtara Therapeutics RevenueProtara Therapeutics EBITProtara Therapeutics Net Income
2029e343.24 M undefined0 undefined101.43 M undefined
2028e200.59 M undefined55.69 M undefined39.07 M undefined
2027e102.69 M undefined-16.12 M undefined-16.83 M undefined
2026e3.77 M undefined-69.07 M undefined-49.94 M undefined
2025e0 undefined-57.66 M undefined-67.34 M undefined
2024e0 undefined-47.35 M undefined-64.44 M undefined
20230 undefined-43.61 M undefined-40.42 M undefined
20220 undefined-37.54 M undefined-65.95 M undefined
20210 undefined-47.49 M undefined-47.25 M undefined
20200 undefined-34.44 M undefined-33.98 M undefined
20190 undefined-15.25 M undefined-14.99 M undefined
20180 undefined-21.37 M undefined-20.73 M undefined
20170 undefined-30.36 M undefined-36.71 M undefined
20160 undefined-28.71 M undefined-28.53 M undefined
20150 undefined-20.87 M undefined-21.38 M undefined
20142.95 M undefined-7.58 M undefined-9.7 M undefined
20130 undefined-7.12 M undefined-14.03 M undefined
20120 undefined-8 M undefined-14.1 M undefined

Protara Therapeutics stock margins

The Protara Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protara Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protara Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Protara Therapeutics's sales revenue. A higher gross margin percentage indicates that the Protara Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Protara Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Protara Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Protara Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Protara Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Protara Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Protara Therapeutics Margin History

Protara Therapeutics Gross marginProtara Therapeutics Profit marginProtara Therapeutics EBIT marginProtara Therapeutics Profit margin
2029e0 %0 %29.55 %
2028e0 %27.76 %19.48 %
2027e0 %-15.7 %-16.39 %
2026e0 %-1,830.05 %-1,323.29 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %-256.95 %-328.81 %
20130 %0 %0 %
20120 %0 %0 %

Protara Therapeutics Aktienanalyse

What does Protara Therapeutics do?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Protara Therapeutics's Profit Margins

The profit margins of Protara Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Protara Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Protara Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Protara Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Protara Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Protara Therapeutics stock

How much profit has Protara Therapeutics made this year?

Protara Therapeutics has made -64.44 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 59.43% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Protara Therapeutics publish its earnings?

Protara Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Protara Therapeutics?

The profits of Protara Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Protara Therapeutics?

You can learn more about the earnings of Protara Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Protara Therapeutics pay?

Over the past 12 months, Protara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protara Therapeutics?

The current dividend yield of Protara Therapeutics is .

When does Protara Therapeutics pay dividends?

Protara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protara Therapeutics?

Protara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protara Therapeutics located?

Protara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protara Therapeutics from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Protara Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Protara Therapeutics in the year 2023?

In the year 2023, Protara Therapeutics distributed 0 USD as dividends.

In which currency does Protara Therapeutics pay out the dividend?

The dividends of Protara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Protara Therapeutics

Our stock analysis for Protara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.